FARMINGTON, Conn., June 26, 2012 /PRNewswire-iReach/ -- As the global economy recovers from recession, the drug discovery industry – which weathered the downturn better than most – are poised for a significant period of new growth. To make the most of this surge in business and make better business decisions, companies need the best, most accurate market data available. Global Information, Inc. is pleased to announce a slate of new drug discovery market forecasts and pipeline assessments from partner publishing firm GlobalData.
The pain management market is ripe with immediate opportunities particularly for reformulations and the generics segment. The looming patent cliff means that generic competition will become increasingly relevant as the current market leaders go off patents. This report provides analyses of key recent licensing and partnership agreements in the acute pain therapeutics market. Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications. Product profiles are included for the following major marketed products in the acute pain therapeutics market: Celebrex, DepoDur, Ofirmev, Oxecta, Nucynta, Dilaudid, Sprix, Zipsor, Flector Patch and Vicoprofen.
Tentative approval from the FDA for generic version of Cymbalta (duloxetine) is on the horizon. The generic market for Cymbalta will be hotly contested despite a U.S. District Court- issued order prohibiting sale of generic duloxetine prior to patent expiry in June 2013. What's the next big thing in the global Osteoarthritis Pain Therapeutics market landscape? - Identify, understand and capitalize by reading this new report.
Bayer recently announced trials of blockbuster Regorafenib have showed promise against gastrointestinal cancer. The German drugmaker added that it will seek approval for wider use of Regorafenib. This report includes molecule profiles for Regorafenib (BAY 73-4506) as well as other late-stage molecules under clinical development including Mastinib, Nexavar (sorafenib) and Tasigna (nilotinib). Clinical trial mapping for gastrointestinal stromal tumors therapeutics is also provided by country, by phase, by trial status, by prominent sponsors and by companies.
Rising demand for hepatitis and HIV testing is set to increase the value of the infectious immunology market. The global infectious immunology market is projected to grow at a CAGR of 7.3% through 2018. The US currently ranks as the largest market for infectious immunology testing with nearly 36% of global revenue. Large testing volumes, high public awareness and reimbursement availability are significant factors contributing to the US infectious immunology testing market. Infectious immunology markets of emerging nations are small relative to developed countries, but they have witnessed the highest growth rates in the past decade. China's infectious immunology market is expected reach revenues close to a billion dollars while the market in India is forecast to reach revenues of nearly $200 million by 2018.
Millions of Americans have hepatitis, but most don't know it. The market for preventative vaccines like Havrix, Vaqta, Twinrix, Ambirix, Avaxim and Epaxal from GlaxoSmithKline, Merck & Co, and Crucell are working to reduce the number of hepatitis contractions worldwide. This report provides information on the key drivers and challenges of the Hepatitis A Preventive Vaccines market.
The traumatic brain injury therapeutics market was valued at $1.25 billion in 2011 and is expected to rise at a compound annual growth rate of 2.8% reaching $1.55 billion by 2019. Traumatic brain injury (TBI) is a major cause of death and disability. An estimated 5.3 million people are living with a permanent TBI-related disability in the U.S. while a third of all injury related deaths are attributed to traumatic brain injury.
An essential source of information and analysis that identifies key trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report provides valuable insights on pipeline products, the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.
The gout space is heating up, but is there sufficient room in the market to accommodate multiple new therapeutics? Major marketed classes of products for treatment of gout include NSAIDs, corticosteroids, Colcrys (Colchicines), Allopurinol, Probenecid, Uloric, Adenuric (febuxostat) and Krystexxa (Pegloticase). In recent news, new analysis of phase III trials showed gout patients with chronic kidney disease responding to Krystexxa. Earlier this month Takeda Pharmaceuticals announced the completion of its acquisition of URL Pharma which will add Colcrys (colchicine) to Takeda's gout treatment portfolio moving forward.
Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
The number of methicillin-resistant staphylococcus aureus (MSRA) infection cases appears to be declining nationwide according to the most recent data release by the U.S. Department of Health and Human Services. In 2005, for every 100,000 people nearly 36 individuals contracted MSRA infections. That number has declined to 21 in 2010. The U.S. government aims to keep infection rates down to 13 per 100,000 people by 2013. This report provides profiles of the most promising drugs used to treat MSRA infections such as Torezolid phosphate (TR-701, Tedizolid), Ceftobiprole Medocaril, Dalbavancin and Oritavancin.
Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market in future. Develop business strategies by understanding the trends shaping and driving the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market.
About Global Information, Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world.
|SOURCE Global Information, Inc.|
Copyright©2012 PR Newswire.
All rights reserved